YOKOGAWA Mariko

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmaceutical Sciences Division of Physics for Life Functions (Shiba-Kyoritsu)

Position

Assistant Professor/Senior Assistant Professor

External Links
Page Top ▲

Academic Degrees 【 Display / hide 】

  • 博士（薬学）, The University of Tokyo, Coursework

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

  • 薬剤師免許

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Life Science / Pharmaceutical analytical chemistry and physicochemistry

  • Life Science / Structural biochemistry

Page Top ▲

Research Keywords 【 Display / hide 】

  • NMR

  • イオンチャネル

  • ウイルス感染症

  • 構造生物学

  • 翻訳因子

Page Top ▲
 

Books 【 Display / hide 】

  • Peptide Toxins Targeting KV Channels

    Matsumura K., Yokogawa M., Osawa M., Handbook of Experimental Pharmacology, 2021

    　View Summary

    A number of peptide toxins isolated from animals target potassium ion (K+) channels. Many of them are particularly known to inhibit voltage-gated K+ (KV) channels and are mainly classified into pore-blocking toxins or gating-modifier toxins. Pore-blocking toxins directly bind to the ion permeation pores of KV channels, thereby physically occluding them. In contrast, gating-modifier toxins bind to the voltage-sensor domains of KV channels, modulating their voltage-dependent conformational changes. These peptide toxins are useful molecular tools in revealing the structure-function relationship of KV channels and have potential for novel treatments for diseases related to KV channels. This review focuses on the inhibition mechanism of pore-blocking and gating-modifier toxins that target KV channels.

  • Nuclear magnetic resonance approaches for characterizing protein-protein interactions

    Toyama Y., Mase Y., Kano H., Yokogawa M., Osawa M., Shimada I., Methods in Molecular Biology, 2018

    　View Summary

    The gating of potassium ion (K+) channels is regulated by various kinds of protein-protein interactions (PPIs). Structural investigations of these PPIs provide useful information not only for understanding the gating mechanisms of K+ channels, but also for developing the pharmaceutical compounds targeting K+ channels. Here, we describe a nuclear magnetic resonance spectroscopic method, termed the cross saturation (CS) method, to accurately determine the binding surfaces of protein complexes, and its application to the investigation of the interaction between a G protein-coupled inwardly rectifying K+ channel and a G protein α subunit.

Page Top ▲

Papers 【 Display / hide 】

  • NMR <sup>1</sup>H, <sup>13</sup>C, <sup>15</sup>N backbone resonance assignments of 14-3-3ζ binding region of human FOXO3a (residues 1-284)

    Enomoto S., Nakatsuka S., Kuwayama T., Kawatsu K., Yokogawa M., Osawa M.

    Biomolecular NMR Assignments 18 ( 2 ) 275 - 283 2024.12

    ISSN  18742718

    　View Summary

    In tumors, mutation in Ras proteins stimulates a signaling cascade through phosphorylation. Downstream of the cascade, many transcription and translation factors are up- or down-regulated by phosphorylation, leading to cancer progression. This phosphorylation cascade is sustained by 14-3-3ζ protein. 14-3-3ζ binds to its client proteins that are Ser/Thr-phosphorylated and prevents their dephosphorylation. One of those transcription factors is FOXO3a, whose transcriptional activity is suppressed in the phosphorylation cascade. FOXO3a binds to specific DNA sequences and activates the transcription of apoptosis-related proteins. In cancer cells, however, FOXO3a is phosphorylated, bound to 14-3-3ζ, and dissociated from the DNA, resulting in FOXO3a inactivation. To elucidate the mechanism of FOXO3a inactivation by the 14-3-3ζ binding, we aim to perform NMR analysis of the interaction between 14-3-3ζ and di-phosphorylated FOXO3a residues 1-284 (dpFOXO3a). Here, we report the backbone resonance assignments of dpFOXO3a, which are transferred from those of the N-terminal domain (NTD) and the DNA-binding domain (DBD) of dpFOXO3a.

  • Ribonuclease inhibitor and angiogenin system regulates cell type–specific global translation

    Stillinovic M., Sarangdhar M.A., Andina N., Tardivel A., Greub F., Bombaci G., Ansermet C., Zatti M., Saha D., Xiong J., Sagae T., Yokogawa M., Osawa M., Heller M., Keogh A., Keller I., Angelillo-Scherrer A., Allam R.

    Science Advances (Science Advances)  10 ( 22 ) eadl0320 2024.05

    　View Summary

    Translation of mRNAs is a fundamental process that occurs in all cell types of multicellular organisms. Conventionally, it has been considered a default step in gene expression, lacking specific regulation. However, recent studies have documented that certain mRNAs exhibit cell type–specific translation. Despite this, it remains unclear whether global translation is controlled in a cell type–specific manner. By using human cell lines and mouse models, we found that deletion of the ribosome-associated protein ribonuclease inhibitor 1 (RNH1) decreases global translation selectively in hematopoietic-origin cells but not in the non–hematopoietic-origin cells. RNH1-mediated cell type–specific translation is mechanistically linked to angiogenin-induced ribosomal biogenesis. Collectively, this study unravels the existence of cell type–specific global translation regulators and highlights the complex translation regulation in vertebrates.

  • Applying deep learning to iterative screening of medium-sized molecules for protein-protein interaction-targeted drug discovery

    Shimizu Y., Yonezawa T., Bao Y., Sakamoto J., Yokogawa M., Furuya T., Osawa M., Ikeda K.

    Chemical Communications (Chemical Communications)  59 ( 44 ) 6722 - 6725 2023.05

    ISSN  13597345

    　View Summary

    We combined a library of medium-sized molecules with iterative screening using multiple machine learning algorithms that were ligand-based, which resulted in a large increase of the hit rate against a protein-protein interaction target. This was demonstrated by inhibition assays using a PPI target, Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-related factor 2 (Keap1/Nrf2), and a deep neural network model based on the first-round assay data showed a highest hit rate of 27.3%. Using the models, we identified novel active and non-flat compounds far from public datasets, expanding the chemical space.

  • TDP-43 N-terminal domain dimerisation or spatial separation by RNA binding decreases its propensity to aggregate

    Miura M., Sakaue F., Matsuno H., Morita K., Yoshida A., Hara R.I., Nishimura R., Nishida Y., Yokogawa M., Osawa M., Yokota T.

    FEBS Letters (FEBS Letters)  597 ( 12 ) 1667 - 1676 2023

    ISSN  00145793

    　View Summary

    Aggregation of the 43 kDa TAR DNA-binding protein (TDP-43) is a pathological hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). RNA binding and TDP-43 N-terminal domain dimerisation has been suggested to ameliorate TDP-43 aggregation. However, the relationship between these factors and the solubility of TDP-43 is largely unknown. Therefore, we developed new oligonucleotides that can recruit two TDP-43 molecules and interfere with their intermolecular interactions via spatial separation. Using these oligonucleotides and TDP-43-preferable UG-repeats, we uncovered two distinct mechanisms for modulating TDP-43 solubility by RNA binding: One is N-terminal domain dimerisation, and the other is the spatial separation of two TDP-43 molecules. This study provides new molecular insights into the regulation of TDP-43 solubility.

  • Paip2A inhibits translation by competitively binding to the RNA recognition motifs of PABPC1 and promoting its dissociation from the poly(A) tail.

    Sagae T, Yokogawa M, Sawazaki R, Ishii Y, Hosoda N, Hoshino SI, Imai S, Shimada I, Osawa M

    The Journal of biological chemistry (Journal of Biological Chemistry)  298 ( 5 ) 101844 2022.03

    ISSN  0021-9258

    　View Summary

    Eukaryotic mRNAs possess a poly(A) tail at their 30-end, to which poly(A)-binding protein C1 (PABPC1) binds and recruits other proteins that regulate translation. Enhanced poly(A)dependent translation, which is also PABPC1 dependent, promotes cellular and viral proliferation. PABP-interacting protein 2A (Paip2A) effectively represses poly(A)-dependent translation by causing the dissociation of PABPC1 from the poly(A) tail; however, the underlying mechanism remains unknown. This study was conducted to investigate the functional mechanisms of Paip2A action by characterizing the PABPC1–poly(A) and PABPC1–Paip2A interactions. Isothermal titration calorimetry and NMR analyses indicated that both interactions predominantly occurred at the RNA recognition motif (RRM) 2–RRM3 regions of PABPC1, which have comparable affinities for poly(A) and Paip2A (dissociation constant, Kd = 1 nM). However, the Kd values of isolated RRM2 were 200 and 4 μM in their interactions with poly(A) and Paip2A, respectively; Kd values of 5 and 1 μM were observed for the interactions of isolated RRM3 with poly(A) and Paip2A, respectively. NMR analyses also revealed that Paip2A can bind to the poly(A)binding interfaces of the RRM2 and RRM3 regions of PABPC1. Based on these results, we propose the following functional mechanism for Paip2A: Paip2A initially binds to the RRM2 region of poly(A)-bound PABPC1, and RRM2-anchored Paip2A effectively displaces the RRM3 region from poly(A), resulting in dissociation of the whole PABPC1 molecule. Together, our findings provide insight into the translation repression effect of Paip2A and may aid in the development of novel anticancer and/or antiviral drugs.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • Nuclear Magnetic Resonance Approaches for Characterizing Protein-Protein Interactions.

    Toyama Y, Mase Y, Kano H, Yokogawa Mariko, Osawa M, Shimada I

    Methods Mol Biol. 1684   115 - 128 2018.10

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work

Page Top ▲

Presentations 【 Display / hide 】

  • Discovery of COVID-19 therapeutic seeds using angiotensin-converting enzyme 2 (ACE2) immobilized beads

    江川 奏, 齋藤 駿, 山本 瑞生, 横川 真梨子, 大澤 匡範, 荻 貴之, 荒井 緑

    日本薬学会第145年会, 

    2025.03

  • Angiotensin-converting enzyme 2 (ACE2) 担持ビーズを用いた 新型コロナウイルス感染症治療薬シードの探索

    江川 奏, 齋藤 駿, 山本 瑞生, 横川 真梨子, 大澤 匡範, 荻 貴之, 荒井 緑

    第10回 食品薬学シンポジウム, 

    2024.10
    , 

    Poster presentation

  • Development of novel anti-HBV drugs based on AI technology using bile acid derivatives to inhibit HBV and NTCP binding

    Okumura A, Ikeda K, Arai J , Muraki Y , Nishimura S, Inden N, Yokogawa M, Yamashita Y, Iguchi Y, Ohashi H, Watashi K, Wakita T, Une M, Osawa M, Ito K

    International HBV Meeting 2024, 

    2024.09
    , 

    Poster presentation

  • 新規Keap1-Nrf2タンパク質間相互作用阻害剤とKeap1結合の構造基盤

    小島 行人, 石田 英子, 原田 彩佳, 米澤 朋起, 清水 祐吾, 池田 和由, 横川 真梨子, 大澤 匡範

    第21回次世代を担う若手のためのフィジカル・ファーマフォーラム (PPF2024) (レクトーレ葉山　湘南国際村) , 

    2024.08
    , 

    Oral presentation (general), 日本薬学会　物理系薬学部会

  • BTG2によるCaf1依存的ポリA分解の促進機構の解明

    片岡 奈緒, 横川 真梨子, 石井 裕一郎, 城 えりか, 高嶋 大翔, 沢崎 綾一, 寒河江 彪流, 尾上 耕一, 星野 真一, 大澤 匡範

    第21回次世代を担う若手のためのフィジカル・ファーマフォーラム (PPF2024)) (レクトーレ葉山　湘南国際村) , 

    2024.08
    , 

    Oral presentation (general), 日本薬学会　物理系薬学部会

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • B型肝炎ウイルスの肝細胞侵入・増殖機構の構造基盤と立体構造に基づく創薬

    2021.04
    -
    2024.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

  • B型肝炎ウイルスの肝細胞侵入および増殖機構の構造生物学的解析

    2018.04
    -
    2021.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

  • Structural basis for hepatitis B virus infection

    2016.04
    -
    2018.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Young Scientists (B), Principal investigator

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • BIOLOGY BASED ON MOLECULAR FUNCTIONS

    2024

  • BASIC PHARMACEUTICAL SCIENCES LABORATORY COURSE

    2024

  • BACHELOR'S THESIS

    2024

  • ADVANCED DRUG DELIVERY AND PHARMACOKINETICS

    2024

  • DOCTORAL LECTURE ON CHEMICAL PHARMACY 1

    2024

display all >>

Page Top ▲

Courses Previously Taught 【 Display / hide 】

  • 薬学基礎実習

    Keio University

    2015.04
    -
    2016.03
    , 

    Autumn Semester, Laboratory work/practical work/exercise

  • C1(4)物質の変化

    Keio University

    2015.04
    -
    2016.03
    , 

    Autumn Semester, Lecture

    反応速度

  • 薬学実習IIA（化学、物理）

    Keio University

    2015.04
    -
    2016.03
    , 

    Spring Semester, Laboratory work/practical work/exercise

Page Top ▲